Anti-Human CCR4 Recombinant Antibody (406) (CAT#: TAB-1524CL)

This single chain antibody fragment which binds to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and is capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. It is also effective in the treatment of tumors, viral infections and other diseases and conditions in which CCR4+ cells are involved such as inflammatory or immune disorders.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
FC

Figure 1 Binding of anti-CCR4 scFvs to target cells, expressing CCR4.

Figure 1 Binding of anti-CCR4 scFvs to target cells, expressing CCR4.

ScFvs were cross-linked using anti-Myc-antibody (mouse) to simulate a dimeric situation and diluted 3-fold, starting at 10 μg/mL. Bound scFvs were detected using RPE-conjugated anti-mouse IgG. a.) Binding to CCR4-positive DT40 cells, b.) Binding to CCR4-negative DT40 cells.

FC

Figure 2 Binding of anti-CCR4 scFvs to natural target cell (CCRF-CEM), expressing CCR4.

Figure 2 Binding of anti-CCR4 scFvs to natural target cell (CCRF-CEM), expressing CCR4.

ScFvs were cross-linked using anti-Myc-antibody (mouse) to simulate a dimeric situation and diluted 3-fold, starting at 20 μg/mL. Bound scFvs were detected using RPE-conjugated anti-mouse IgG.

Figure 3 Ligand-interfering binding experiments of anti-CCR4 scFvs using Alexa647-labeled MDC-SNAP.

Figure 3 Ligand-interfering binding experiments of anti-CCR4 scFvs using Alexa647-labeled MDC-SNAP.

ScFvs were incubated at a concentration of 5 μg/mL (150 nM) and diluted 3-fold over twelve dilution points in the presence of a fixed concentration of MDC-SNAP (50 nM).

Figure 4 Ligand-interfering binding experiments of anti-CCR4 scFvs in presence of TARC and MDC.

Figure 4 Ligand-interfering binding experiments of anti-CCR4 scFvs in presence of TARC and MDC.

ScFvs were incubated at a concentration of 0.5 μg/mL in presence of 2.5 μg/mL mouse anti-Myc-antibody (mouse) in presence of a fixed concentration of ligands (1 μg/mL) and stained using an anti-mouse-RPE conjugated antibody. Signals were compared to cells, stained only with antibody-controls (background) as well as to unstained cells (unstained).

Figure 5 Competition experiment between anti-CCR4 antibodies 208, 306, 308, 406, 501, 503, 601, 60, 803 and KM3060var in presence of biotinylated KW0761-lgG.

Figure 5 Competition experiment between anti-CCR4 antibodies 208, 306, 308, 406, 501, 503, 601, 60, 803 and KM3060var in presence of biotinylated KW0761-lgG.

The biotinylated KW0761-lgG was detected using PE-conjugated Streptavidin.

Inhib

Figure 6 Inhibition of TARC-mediated Ca-Flux by anti-CCR4 scFv antibodies in comparison to KM3060var.

Figure 6 Inhibition of TARC-mediated Ca-Flux by anti-CCR4 scFv antibodies in comparison to KM3060var.

TARC was incubated at a final concentration of 28.6 ng/μL (3.6 nM) in presence of increasing scFv-concentrations, titrated over six dilution points, starting at 0.5 μg/mL. The signals were expressed in % where 100% signaling refers to recorded signals in presence of TARC-ligand, but no scFv antibody.

Inhib

Figure 7 Inhibition of MDC-mediated Ca-Flux by anti-CCR4 scFv antibodies.

Figure 7 Inhibition of MDC-mediated Ca-Flux by anti-CCR4 scFv antibodies.

MDC was incubated at a final concentration of 5 ng/μL (6.25 nM) in presence of a fixed scFv concentration of 10 μg/mL. The signals were expressed in % where 100% signaling refers to recorded signals in presence of MDC-ligand, but no scFv antibody.

Inhib

Figure 8 Inhibition of TARC-mediated chemotaxis on CCR4+ CCRF-CEM cells in presence of increasing concentrations of anti-CCR4 scFv antibodies (0.36 to 333 nM).

Figure 8 Inhibition of TARC-mediated chemotaxis on CCR4+ CCRF-CEM cells in presence of increasing concentrations of anti-CCR4 scFv antibodies (0.36 to 333 nM).

TARC had a fixed concentration of 3.5 nM. The signals were expressed in % where 100% refers to migration of cells in presence of TARC-ligand, but no scFv antibody. The graphs were fitted.

FC

Figure 9 Binding of anti-CCR4 IgGs to target cells expressing CCR4.

Figure 9 Binding of anti-CCR4 IgGs to target cells expressing CCR4.

IgGs were incubated at defined concentrations and bound IgGs were detected using RPE-conjugated anti-Human IgG. a.) Binding to CCR4-positive CCRF-CEM cells. IgGs were diluted four-fold over eight points starting at 1 μg/ml. b.) Binding to CCR4-positive Hut78 cells. IgGs were diluted four-fold over eight points starting at 1 μg/ml. c.) Binding to CCR4-positive L-428 cells. IgGs were diluted three-fold over eight points starting at 10 μg/ml.

Figure 10 Binding to CCR4-expressing target cells (CCRF-CEM) in presence of human serum.

Figure 10 Binding to CCR4-expressing target cells (CCRF-CEM) in presence of human serum.

Biotinylated samples were incubated at 10 μg/ml in either 0% human serum (FACS-buffer) or in 10 and 50% human serum. Samples were detected via PE-conjugated-Streptavidin. a.) Comparison of recorded binding signals, b.) Remaining binding signals converted into %.


Specifications

  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • Human antibody
  • Specificity
  • Human
  • Clone
  • 406
  • Applications
  • FC, Inhib
  • Related Disease
  • Tumors, viral infections and other diseases and conditions in which CCR4+ cells are involved such as inflammatory or immune disorders

Applications

  • Application Notes
  • This antibody has been tested for use in Flow Cytometry and Inhibition.

Target

  • Alternative Names
  • CCR4; chemokine (C-C motif) receptor 4; CKR4; K5-5; CD194; CMKBR4; ChemR13; CC-CKR-4; HGCN:14099; C-C chemokine receptor type 4; CCR-4; C-C CKR-4; chemokine (C-C) receptor 4

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 406"

See other products for "CCR4"

Recombinant Antibody

CAT Product Name Application Type
MOB-1992z Mouse Anti-CCR4 Recombinant Antibody (clone 42C4) WB, FC, ICC, IF Mouse IgG2a
MOB-0370CT Mouse Anti-CCR4 Recombinant Antibody (clone LI-5G6) ELISA, FC, IF Mouse IgG2a
HPAB-0141-LSX Mouse Anti-CCR4 Recombinant Antibody (HPAB-0141-LSX) ELISA, WB, FC, ADCC, CDC, FuncS Mouse IgG2b
HPAB-0143-LSX Human Anti-CCR4 Recombinant Antibody (HPAB-0143-LSX) ELISA, WB, FC, ADCC, CDC, FuncS Human IgG
VS4-WK72 Human Anti-CCR4 Recombinant Antibody (clone 12F5) ELISA, FC Human IgG1

Humanized Antibody

Immunotoxin

CAT Product Name Application Type
AGTO-G005D Anti-CCR4 immunotoxin (scFv)-DT Cytotoxicity assay, Function study

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-187 Afuco™ Anti-CCR4 Recombinant Antibody (AFC-TAB-187), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC Human IgG1, κ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-1524CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare